Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–48.
Article
CAS
PubMed
Google Scholar
Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer—The California cancer registry, 1999–2004. Cancer. 2008;112(4):737–47.
Article
PubMed
Google Scholar
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429–34.
Article
PubMed
Google Scholar
Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275–81.
Article
PubMed
Google Scholar
Amaravadi R, Kimmelman AC, White E. Recent insights into the function of autophagy in cancer. Genes Dev. 2016;30(17):1913–30.
Article
CAS
PubMed
PubMed Central
Google Scholar
White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer. 2012;12(6):401–10.
Article
CAS
PubMed
PubMed Central
Google Scholar
Perez-Hernandez M, Arias A, Martinez-Garcia D, Perez-Tomas R, Quesada R, Soto-Cerrato V. Targeting autophagy for cancer treatment and tumor chemosensitization. Cancers. 2019;11(10):1599.
Article
CAS
PubMed Central
Google Scholar
Kimura T, Takabatake Y, Takahashi A, Isaka Y. Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res. 2013;73(4):1446.
Article
CAS
Google Scholar
Zhang T, Li J, Yin F, Lin B, Wang Z, Xu J, et al. Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3. Oncogene. 2017;36(47):6627–39.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang G, Feng CC, Chu SJ, Zhang R, Lu YM, Zhu JS, et al. Toosendanin inhibits growth and induces apoptosis in colorectal cancer cells through suppression of AKT/GSK-3 beta/beta-catenin pathway. Int J Oncol. 2015;47(5):1767–74.
Article
CAS
PubMed
Google Scholar
Luo W, Liu X, Sun W, Lu JJ, Wang Y, Chen XJPR. Toosendanin, a natural product, inhibited TGF-β1-induced epithelial-mesenchymal transition through ERK/Snail pathway. Phytother Res. 2018;32(10):2009–20.
Article
CAS
PubMed
Google Scholar
Wang HH, Wen CY, Chen SY, Wang F, He L, Li WQ, et al. Toosendanin-induced apoptosis in colorectal cancer cells is associated with the kappa-opioid receptor/beta-catenin signaling axis. Biochem Pharmacol. 2020;177:114014.
Article
CAS
PubMed
Google Scholar
Zhang JN, Yang F, Mei XY, Yang R, Lu B, Wang ZT, et al. Toosendanin and isotoosendanin suppress triple-negative breast cancer growth via inducing necrosis, apoptosis and autophagy. Chemico-Biol Interact. 2022;351:109739.
Article
CAS
Google Scholar
de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet. 2018;57(10):1229–54.
Article
PubMed
PubMed Central
CAS
Google Scholar
Paillas S, Causse A, Marzi L, De Medina P, Poirot M, Denis V, et al. MAPK14/p38 alpha confers irinotecan resistance to TP53-defective cells by inducing survival autophagy. Autophagy. 2012;8(7):1098–112.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63.
Article
CAS
PubMed
Google Scholar
Kliosnky D. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12(2):443.
Google Scholar
Mauthe M, Orhon I, Rocchi C, Zhou XD, Luhr M, Hijlkema KJ, et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 2018;14(8):1435–55.
Article
CAS
PubMed
PubMed Central
Google Scholar
Guha S, Padh H. Cathepsins: fundamental effectors of endolysosomal proteolysis. Indian J Biochem Biophys. 2008;45(2):75–90.
CAS
PubMed
Google Scholar
Chittaranjan S, Bortnik S, Dragowska WH, Xu J, Abeysundara N, Leung A, et al. Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer. Clin Cancer Res. 2014;20(12):3159–73.
Article
CAS
PubMed
Google Scholar
Wu MY, Wang SF, Cai CZ, Tan JQ, Li M, Lu JJ, et al. Natural autophagy blockers, dauricine (DAC) and daurisoline (DAS), sensitize cancer cells to camptothecin-induced toxicity. Oncotarget. 2017;8(44):77673–84.
Article
PubMed
PubMed Central
Google Scholar
Coussy F, El-Botty R, Chateau-Joubert S, Dahmani A, Montaudon E, Leboucher S, et al. BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. Sci Transl Med. 2020;12(531):eaax2625.
Article
CAS
PubMed
PubMed Central
Google Scholar
Townsend KN, Hughson LRK, Schlie K, Poon VI, Westerback A, Lum JJ. Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity. Immunol Rev. 2012;249:176–94.
Article
CAS
PubMed
Google Scholar
Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer. 2017;17(9):528–42.
Article
CAS
PubMed
Google Scholar
Feng Y, Gao YJ, Wang DY, Xu ZH, Sun WX, Ren P. Autophagy inhibitor (LY294002) and 5-fluorouracil (5-FU) combination-based nanoliposome for enhanced efficacy against esophageal squamous cell carcinoma. Nanoscale Res Lett. 2018;13:325.
Article
PubMed
PubMed Central
CAS
Google Scholar
Wu YY, Wang X, Guo HJ, Zhang B, Zhang XB, Shi ZJ, et al. Synthesis and screening of 3-MA derivatives for autophagy inhibitors. Autophagy. 2013;9(4):595–603.
Article
CAS
PubMed
PubMed Central
Google Scholar
Calcagno AM, Fostel JM, To KK, Salcido CD, Martin SE, Chewning KJ, et al. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. Br J Cancer. 2008;98(9):1515–24.
Article
CAS
PubMed
PubMed Central
Google Scholar
Grassilli E, Ballabeni A, Maellaro E, Del Bello B, Helin K. Loss of MYC confers resistance to doxorubicin-induced apoptosis by preventing the activation of multiple serine protease- and caspase-mediated pathways. J Biol Chem. 2004;279(20):21318–26.
Article
CAS
PubMed
Google Scholar
Luo W, Liu X, Sun W, Lu JJ, Wang YT, Chen XP. Toosendanin, a natural product, inhibited TGF-1-induced epithelial-mesenchymal transition through ERK/Snail pathway. Phytother Res. 2018;32(10):2009–20.
Article
CAS
PubMed
Google Scholar
Xie F, Zhang M, Zhang CF, Wang ZT, Yu BY, Kou JP. Anti-inflammatory and analgesic activities of ethanolic extract and two limonoids from Melia toosendan fruit. J Ethnopharmacol. 2008;117(3):463–6.
Article
CAS
PubMed
Google Scholar
Shao SL, Li SS, Liu C, Zhang WW, Zhang ZZ, Zhu SW, et al. Toosendanin induces apoptosis of MKN-45 human gastric cancer cells partly through miR-23a-3p-mediated downregulation ofBCL2. Mol Med Rep. 2020;22(3):1793–802.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang Q, Wang Z, Hou GL, Huang P. Toosendanin suppresses glioma progression property and induces apoptosis by regulating miR-608/Notch Axis. Cancer Manage Res. 2020;12:3419–31.
Article
CAS
Google Scholar
Gao T, Xie A, Liu XQ, Zhan HB, Zeng J, Dai M, et al. Toosendanin induces the apoptosis of human Ewing’s sarcoma cells via the mitochondrial apoptotic pathway. Mol Med Rep. 2019;20(1):135–40.
CAS
PubMed
PubMed Central
Google Scholar
He YJ, Wang J, Liu XL, Zhang L, Yi G, Li CW, et al. Toosendanin inhibits hepatocellular carcinoma cells by inducing mitochondria-dependent apoptosis. Planta Med. 2010;76(13):1447–53.
Article
CAS
PubMed
Google Scholar
Tada K, Takido M, Kitanaka S. Limonoids from fruit of Melia toosendan and their cytotoxic activity. Phytochemistry. 1999;51(6):787–91.
Article
CAS
PubMed
Google Scholar
Li X, You M, Liu YJ, Ma L, Jin PP, Zhou R, et al. Reversal of the apoptotic resistance of non-small-cell lung carcinoma towards TRAIL by natural product Toosendanin. Sci Rep. 2017;7:42748.
Article
CAS
PubMed
PubMed Central
Google Scholar
Dong Y, Hu YJ, Sarkar S, Zong WX, Li M, Feng D, et al. Autophagy modulator scoring system: a user-friendly tool for quantitative analysis of methodological integrity of chemical autophagy modulator studies. Autophagy. 2020;16(2):195–202.
Article
CAS
PubMed
Google Scholar
Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy. 2021;17(1):1–382.
Article
PubMed
PubMed Central
Google Scholar
Shi Y-L, Wang W-P. Biological effects of toosendanin, an active ingredient of herbal vermifuge in Chinese traditional medicine. Sheng Li Xue Bao. 2006;58(5):397–406.
CAS
PubMed
Google Scholar
Zhuo Y, Zhang YD, Li M, Wu HY, Gong SL, Hu XL, et al. Hepatotoxic evaluation of toosendanin via biomarker quantification and pathway mapping of large-scale chemical proteomics. Food Chem Toxicol. 2021;153:112257.
Article
CAS
PubMed
Google Scholar
Das CK, Linder B, Bonn F, Rothweiler F, Dikic I, Michaelis M, et al. BAG3 overexpression and cytoprotective autophagy mediate apoptosis resistance in chemoresistant breast cancer cells. Neoplasia. 2018;20(3):263–79.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wu M, Zhang PH. EGFR-mediated autophagy in tumourigenesis and therapeutic resistance. Cancer Lett. 2020;469:207–16.
Article
CAS
PubMed
Google Scholar
Zheng K, He ZD, Kitazato K, Wang YF. Selective autophagy regulates cell cycle in cancer therapy. Theranostics. 2019;9(1):104–25.
Article
CAS
PubMed
PubMed Central
Google Scholar
Fenn KM, Kalinsky K. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors. Drugs Today. 2019;55(9):575–85.
Article
CAS
Google Scholar
Lin HC, Chuang CH, Cheng MH, Lin YC, Fang YP. High potency of SN-38-loaded bovine serum albumin nanoparticles against triple-negative breast cancer. Pharmaceutics. 2019;11(11):569.
Article
CAS
PubMed Central
Google Scholar
Cao L, Qu DD, Wang H, Zhang SM, Jia CM, Shi ZX, et al. Toosendanin exerts an anti-cancer effect in glioblastoma by inducing estrogen receptor beta-and p53-mediated apoptosis. Int J Mol Sci. 2016;17(11):1928.
Article
PubMed Central
CAS
Google Scholar
Pei Z, Fu W, Wang GP. A natural product toosendanin inhibits epithelial-mesenchymal transition and tumor growth in pancreatic cancer via deactivating Akt/mTOR signaling. Biochem Biophys Res Commun. 2017;493(1):455–60.
Article
CAS
PubMed
Google Scholar
Fan HN, Chen W, Zhu JS, Zhang J, Peng SQ. Toosendanin alleviates dextran sulfate sodium-induced colitis by inhibiting M1 macrophage polarization and regulating NLRP3 inflammasome and Nrf2/HO-1 signaling. Int Immunopharmacol. 2019;76:105909.
Article
CAS
PubMed
Google Scholar
Zheng MD, Wang ND, Li XL, Yan J, Tang JH, Zhao XH, et al. Toosendanin mediates cisplatin sensitization through targeting Annexin A4/ATP7A in non-small cell lung cancer cells. J Nat Med. 2018;72(3):724–33.
Article
CAS
PubMed
Google Scholar